Literature DB >> 19114959

Capsaicin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine pulmonary arteries.

Ajay K Dhadwal1, Xinwen Wang, Suman Annambhotla, Peter H Lin, Qizhi Yao, Changyi Chen.   

Abstract

BACKGROUND: Highly active antiretroviral therapy (HAART) including HIV protease inhibitor ritonavir may be associated with the clinical complications including accelerated atherosclerosis and pulmonary artery hypertension. The objective of this study was to determine whether capsaicin, a major ingredient of hot pepper with antioxidative property, could effectively inhibit ritonavir-induced oxidative injury in porcine pulmonary arteries. MATERIAL/
METHODS: Fresh porcine pulmonary artery rings were treated with ritonavir (15 microM), capsaicin (50 microM) or both for 24 hours and, then, subjected to myograph analysis in response to vasoactive drugs including thromboxane A2 analog U-46619, bradykinin, and sodium nitroprusside (SNP).
RESULTS: In response to U-46619 (3x10(-8) M), ritonavir-treated porcine pulmonary artery rings reduced the contraction by 15% compared with control rings. In response to bradykinin (10(-6) M), ritonavir-treated rings showed a significant reduction of endothelium-dependent vasorelaxation by 32% compared with untreated control vessels (P<0.05, n=5, Student t-test). However, ritonavir treatment did not change endothelium-independent vasorelaxation in response to SNP (10(-6) M). Capsaicin-treated vessel rings did not show any significant changes in response to U-46619, bradykinin, and SNP compared with untreated control vessels. More importantly, capsaicin co-cultured with ritonavir significantly blocked ritonavir-induced inhibition of endothelium-dependent vasorelaxation and contraction compared with ritonavir alone treatment in porcine pulmonary artery rings (P<0.05, n=5, Student t-test).
CONCLUSIONS: Capsaicin effectively inhibits the detrimental effects of HIV protease inhibitor ritonavir on vasomotor functions of porcine pulmonary arteries. These findings may suggest that capsaicin could have clinical applications to prevent vascular and pulmonary complications of HAART drugs in HIV patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19114959      PMCID: PMC2932636     

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  26 in total

Review 1.  Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review.

Authors:  David C Rhew; Myriam Bernal; Daniel Aguilar; Uchenna Iloeje; Matthew Bidwell Goetz
Journal:  Clin Infect Dis       Date:  2003-09-12       Impact factor: 9.079

2.  Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels.

Authors:  J N Wilcox; R R Subramanian; C L Sundell; W R Tracey; J S Pollock; D G Harrison; P A Marsden
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

3.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

Review 4.  Endothelial function and oxidant stress.

Authors:  D G Harrison
Journal:  Clin Cardiol       Date:  1997-11       Impact factor: 2.882

5.  Primary pulmonary hypertension in HIV infection.

Authors:  R Speich; R Jenni; M Opravil; M Pfab; E W Russi
Journal:  Chest       Date:  1991-11       Impact factor: 9.410

Review 6.  Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infection.

Authors:  Bruno R Cotter; Francesca J Torriani
Journal:  Cardiovasc Toxicol       Date:  2004       Impact factor: 3.231

7.  Generation of superoxide by purified brain nitric oxide synthase.

Authors:  S Pou; W S Pou; D S Bredt; S H Snyder; G M Rosen
Journal:  J Biol Chem       Date:  1992-12-05       Impact factor: 5.157

8.  Role of human immunodeficiency virus in primary pulmonary hypertension--case reports.

Authors:  A M Pellicelli; F Palmieri; C D'Ambrosio; A Rianda; E Boumis; E Girardi; G Antonucci; C D'Amato; M C Borgia
Journal:  Angiology       Date:  1998-12       Impact factor: 3.619

Review 9.  Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management.

Authors:  Leonardo Calza; Roberto Manfredi; Francesco Chiodo
Journal:  Int J Antimicrob Agents       Date:  2003-08       Impact factor: 5.283

10.  Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.

Authors:  H Shimokawa; N A Flavahan; P M Vanhoutte
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more
  4 in total

1.  The soybean isoflavonoid equol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells.

Authors:  Charlie Cheng; Xinwen Wang; Sarah M Weakley; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  J Nutr       Date:  2009-11-18       Impact factor: 4.798

2.  Lactosylceramide causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells.

Authors:  Jean Bismuth; Hong Chai; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2009-09

3.  Natural antioxidant dihydroxybenzyl alcohol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human endothelial cells.

Authors:  Sarah M Weakley; Jun Jiang; Jianming Lü; Xinwen Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2011-09

4.  Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.

Authors:  Jian-Ming Lü; Jacobo Nurko; Jun Jiang; Sarah M Weakley; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2011-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.